Phase 2 study of TAK-442, an oral factor Xa inhibitor, in patients following acute coronary syndrome.

Goldstein S, Bates ER, Bhatt DL, Cao C, Holmes D, Kupfer S, Martinez F, Spaeder J, Weitz JI, Ye Z, Zannad F, AXIOM investigators

Open source

DOI
10.1160/th13-07-0543
Published
2014 Jun
Container
Thrombosis and haemostasis
Publisher
Not recorded
Open access
unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1160/th13-07-0543,
  title = {Phase 2 study of TAK-442, an oral factor Xa inhibitor, in patients following acute coronary syndrome.},
  author = {Goldstein S and Bates ER and Bhatt DL and Cao C and Holmes D and Kupfer S and Martinez F and Spaeder J and Weitz JI and Ye Z and Zannad F and AXIOM investigators},
  year = {2014},
  journal = {Thrombosis and haemostasis},
  doi = {10.1160/th13-07-0543},
  url = {https://doi.org/10.1160/th13-07-0543}
}

RIS

TY  - JOUR
TI  - Phase 2 study of TAK-442, an oral factor Xa inhibitor, in patients following acute coronary syndrome.
AU  - Goldstein S
AU  - Bates ER
AU  - Bhatt DL
AU  - Cao C
AU  - Holmes D
AU  - Kupfer S
AU  - Martinez F
AU  - Spaeder J
AU  - Weitz JI
AU  - Ye Z
AU  - Zannad F
AU  - AXIOM investigators
PY  - 2014
JO  - Thrombosis and haemostasis
DO  - 10.1160/th13-07-0543
UR  - https://doi.org/10.1160/th13-07-0543
ER  - 

APA

S, G., ER, B., DL, B., C, C., D, H., S, K., F, M., J, S., JI, W., Z, Y., F, Z., & investigators, A. (2014). Phase 2 study of TAK-442, an oral factor Xa inhibitor, in patients following acute coronary syndrome.. Thrombosis and haemostasis. https://doi.org/10.1160/th13-07-0543

Source records